These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 33595891)

  • 1. Immunotherapy for the treatment of colorectal cancer.
    Lumish MA; Cercek A
    J Surg Oncol; 2021 Mar; 123(3):760-774. PubMed ID: 33595891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
    Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
    Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective.
    Liu N; Shan F; Ma M
    Int Immunopharmacol; 2021 Oct; 99():108017. PubMed ID: 34352568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the efficacy and safety of first- and second-line immunotherapy in patients with metastatic colorectal cancer: a systematic review and network meta-analysis based on randomized controlled trials.
    Chen K; Chen W; Yue R; Zhu D; Cui S; Zhang X; Jin Z; Xiao T
    Front Immunol; 2024; 15():1439624. PubMed ID: 39359729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study.
    Marolleau P; Tougeron D; Allignet B; Cohen R; Sefrioui D; Gallet B; Dumont F; Guimbaud R; Alouani E; Passot G; Desolneux G; Ghiringhelli F; Marchal F; Mourthadhoi F; Coriat R; Desgrippes R; Locher C; Goujon G; Des Guetz G; Aparicio T; Paubelle E; Dupré A; de la Fouchardière C
    Int J Cancer; 2023 Oct; 153(7):1376-1385. PubMed ID: 37403609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial.
    Gallois C; Emile JF; Kim S; Monterymard C; Gilabert M; Bez J; Lièvre A; Dahan L; Laurent-Puig P; Mineur L; Coriat R; Legoux JL; Hautefeuille V; Phelip JM; Lecomte T; Sokol H; Capron C; Randrian V; Lepage C; Lomenie N; Kurtz C; Taieb J; Tougeron D
    Dig Liver Dis; 2021 Oct; 53(10):1254-1259. PubMed ID: 34215534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond.
    Cohen R; Rousseau B; Vidal J; Colle R; Diaz LA; André T
    Target Oncol; 2020 Feb; 15(1):11-24. PubMed ID: 31786718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma.
    Almquist DR; Ahn DH; Bekaii-Saab TS
    BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.
    Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC
    Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the efficiency of immune checkpoint inhibitors for metastatic pMMR/MSS colorectal cancer: Options and strategies.
    Yang C; Zhao L; Lin Y; Wang S; Ye Y; Shen Z
    Crit Rev Oncol Hematol; 2024 Aug; 200():104204. PubMed ID: 37984588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
    Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability.
    Ratovomanana T; Nicolle R; Cohen R; Diehl A; Siret A; Letourneur Q; Buhard O; Perrier A; Guillerm E; Coulet F; Cervera P; Benusiglio P; Labrèche K; Colle R; Collura A; Despras E; Le Rouzic P; Renaud F; Cros J; Alentorn A; Touat M; Ayadi M; Bourgoin P; Prunier C; Tournigand C; Fouchardière C; Tougeron D; Jonchère V; Bennouna J; de Reynies A; Fléjou JF; Svrcek M; André T; Duval A
    Ann Oncol; 2023 Aug; 34(8):703-713. PubMed ID: 37269904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.
    Evrard C; Messina S; Sefrioui D; Frouin É; Auriault ML; Chautard R; Zaanan A; Jaffrelot M; De La Fouchardière C; Aparicio T; Coriat R; Godet J; Silvain C; Randrian V; Sabourin JC; Guimbaud R; Miquelestorena-Standley E; Lecomte T; Moulin V; Karayan-Tapon L; Tachon G; Tougeron D
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Microsatellite-Stable Metastatic Colorectal Cancer: Can we close the Gap between Potential and Practice?
    Hamid MA; Pammer LM; Lentner TK; Doleschal B; Gruber R; Kocher F; Gasser E; Jöbstl A; Seeber A; Amann A
    Curr Oncol Rep; 2024 Oct; 26(10):1258-1270. PubMed ID: 39080202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite Stable Colorectal Cancer With an Immunogenic Phenotype: Challenges in Diagnosis and Treatment.
    Saller J; Qin D; Felder S; Coppola D
    Clin Colorectal Cancer; 2020 Jun; 19(2):123-131. PubMed ID: 32171644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.
    Wang Q; Shen X; Chen G; Du J
    Int J Cancer; 2023 Aug; 153(4):709-722. PubMed ID: 36752642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
    Quiroga D; Lyerly HK; Morse MA
    Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
    Zhang X; Wu T; Cai X; Dong J; Xia C; Zhou Y; Ding R; Yang R; Tan J; Zhang L; Zhang Y; Wang Y; Dong C; Li Y
    Front Immunol; 2022; 13():795972. PubMed ID: 35371084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.